Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05085028
Title A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (REFINE-Lung)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Imperial College London
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.